Will Lilly’s eloraTZP phase 2 results at EASD show at least 20% average weight loss?

Question

This market will resolve YES if Lilly’s EASD 2026 phase 2 presentation for the combination of eloralintide and tirzepatide reports a mean body-weight reduction of at least 20.0% from baseline in at least one prespecified combination-treatment arm at that study's primary weight endpoint. Exactly 20.0% qualifies. Use the efficacy estimand if reported; if it is not reported, use the study's explicitly designated primary estimand.

The threshold is the absolute percentage reduction in the combinatio

Problyx · Accepted Answer

Yes — the community forecast puts this at 61%.

Problyx · Answer

No — the community forecast puts this at 39%.